{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:34:02Z","timestamp":1791387242608,"version":"4.3.3"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00728-8","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:01:55Z","timestamp":1743303715000},"page":"681-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Understanding Depression in People Living with Multiple Sclerosis: A Narrative Review of Recent Literature"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7723-8218","authenticated-orcid":false,"given":"Amy B.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Chiong-Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"728_CR1","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, US Multiple Sclerosis Prevalence Workgroup, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92:e1029\u201340.","journal-title":"Neurology"},{"key":"728_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41398-023-02555-7","volume":"13","author":"M Margoni","year":"2023","unstructured":"Margoni M, Preziosa P, Rocca MA, Filippi M. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl Psychiatry. 2023;13:264.","journal-title":"Transl Psychiatry"},{"key":"728_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/13524585211023352","volume":"28","author":"TR Valentine","year":"2022","unstructured":"Valentine TR, Alschuler KN, Ehde DM, Kratz AL. Prevalence, co-occurrence, and trajectories of pain, fatigue, depression, and anxiety in the year following multiple sclerosis diagnosis. Mult Scler. 2022;28:620\u201331.","journal-title":"Mult Scler"},{"key":"728_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s13104-017-2958-1","volume":"10","author":"RA Marrie","year":"2017","unstructured":"Marrie RA, Walld R, Bolton JM, CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease, et al. Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data. BMC Res Notes. 2017;10:619.","journal-title":"BMC Res Notes"},{"key":"728_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7224\/1537-2073.2014-084","volume":"17","author":"A Raissi","year":"2015","unstructured":"Raissi A, Bulloch AG, Fiest KM, McDonald K, Jette N, Patten SB. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care. 2015;17:292\u2013300.","journal-title":"Int J MS Care"},{"key":"728_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamapsychiatry.2017.4602","volume":"75","author":"DS Hasin","year":"2018","unstructured":"Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiat. 2018;75:336\u201346.","journal-title":"JAMA Psychiat"},{"key":"728_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatry Res. 2012;21:169\u201384.","journal-title":"Int J Methods Psychiatry Res"},{"key":"728_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.mayocpiqo.2021.11.004","volume":"6","author":"MD Peterson","year":"2021","unstructured":"Peterson MD, Lin P, Kamdar N, Marsack-Topolewski CN, Mahmoudi E. Physical and mental health comorbidities among adults with multiple sclerosis. Mayo Clin Proc Innov Qual Outcomes. 2021;6:55\u201368.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"728_CR9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7224\/1537-2073.2016-110","volume":"20","author":"RA Marrie","year":"2018","unstructured":"Marrie RA, Patten SB, Berrigan LI, CIHR Team in the Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS), et al. Diagnoses of depression and anxiety versus current symptoms and quality of life in multiple sclerosis. Int J MS Care. 2018;20:76\u201384.","journal-title":"Int J MS Care"},{"key":"728_CR10","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.msard.2019.101919","volume":"40","author":"M Ploughman","year":"2020","unstructured":"Ploughman M, Wallack EM, Chatterjee T, Kirkland MC, Curtis ME, Health Lifestyle and Aging with MS Consortium. Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis. Mult Scler Relat Disord. 2020;40:101919.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR11","doi-asserted-by":"publisher","first-page":"105648","DOI":"10.1016\/j.msard.2024.105648","volume":"87","author":"CA Young","year":"2024","unstructured":"Young CA, Langdon D, Rog D, TONiC study group, et al. Prevalence, treatment and correlates of depression in multiple sclerosis. Mult Scler Relat Disord. 2024;87:105648.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR12","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.apmr.2019.11.005","volume":"101","author":"ES Gromisch","year":"2020","unstructured":"Gromisch ES, Turner AP, Leipertz SL, Beauvais J, Haselkorn JK. Risk factors for suboptimal medication adherence in persons with multiple sclerosis: development of an electronic health record-based explanatory model for disease-modifying therapy use. Arch Phys Med Rehabil. 2020;101:807\u201314.","journal-title":"Arch Phys Med Rehabil"},{"key":"728_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.7150\/ijms.51172","volume":"18","author":"A Koltuniuk","year":"2021","unstructured":"Koltuniuk A, Rosinczuk J. The levels of depression, anxiety, acceptance of illness, and medication adherence in patients with multiple sclerosis\u2014descriptive and correlational study. Int J Med Sci. 2021;18:216\u201325.","journal-title":"Int J Med Sci"},{"key":"728_CR14","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00415-021-10850-w","volume":"269","author":"F Washington","year":"2022","unstructured":"Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022;269:1861\u201372.","journal-title":"J Neurol"},{"key":"728_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/abm\/kaaa102","volume":"55","author":"LM Knowles","year":"2021","unstructured":"Knowles LM, Arewasikporn A, Kratz AL, Turner AP, Alschuler KN, Ehde DM. Early treatment improvements in depression are associated with overall improvements in fatigue impact and pain interference in adults with multiple sclerosis. Ann Behav Med. 2021;55:833\u201343.","journal-title":"Ann Behav Med"},{"key":"728_CR16","doi-asserted-by":"publisher","first-page":"e2216","DOI":"10.1212\/WNL.0000000000008617","volume":"93","author":"S Binzer","year":"2019","unstructured":"Binzer S, McKay KA, Brenner P, Hillert J, Manouchehrinia A. Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. Neurology. 2019;93:e2216\u201323.","journal-title":"Neurology"},{"key":"728_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1176\/appi.neuropsych.18010011","volume":"31","author":"S Gill","year":"2019","unstructured":"Gill S, Santo J, Blair M, Morrow SA. Depressive symptoms are associated with more negative functional outcomes than anxiety symptoms in persons with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2019;31:37\u201342.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"728_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.msard.2019.06.012","volume":"34","author":"Q Shen","year":"2019","unstructured":"Shen Q, Lu H, Xie D, Wang H, Zhao Q, Xu Y. Association between suicide and multiple sclerosis: an updated meta-analysis. Mult Scler Relat Disord. 2019;34:83\u201390.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102904","volume":"51","author":"CD Jones","year":"2021","unstructured":"Jones CD, Motl R, Sandroff BM. Depression in multiple sclerosis: is one approach for its management enough? Mult Scler Relat Disord. 2021;51: 102904.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200154","volume":"13","author":"GE McIntosh","year":"2023","unstructured":"McIntosh GE, Liu ES, Allan M, Grech LB. Clinical practice guidelines for the detection and treatment of depression in multiple sclerosis: a systematic review. Neurol Clin Pract. 2023;13: e200154.","journal-title":"Neurol Clin Pract"},{"key":"728_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028936","volume":"8","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8: a028936.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"728_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.biopsych.2023.11.010","volume":"95","author":"EB Baller","year":"2024","unstructured":"Baller EB, Sweeney EM, Cieslak M, et al. Mapping the relationship of white matter lesions to depression in multiple sclerosis. Biol Psychiatry. 2024;95:1072\u201380.","journal-title":"Biol Psychiatry"},{"key":"728_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s44220-022-00002-y","volume":"1","author":"SH Siddiqi","year":"2023","unstructured":"Siddiqi SH, Kletenik I, Anderson MC, et al. Lesion network localization of depression in multiple sclerosis. Nat Ment Health. 2023;1:36\u201344.","journal-title":"Nat Ment Health"},{"key":"728_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00415-020-10110-3","volume":"268","author":"K Ashton","year":"2021","unstructured":"Ashton K, Fuchs TA, Oship D, et al. Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. J Neurol. 2021;268:169\u201377.","journal-title":"J Neurol"},{"key":"728_CR25","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s10072-024-07316-y","volume":"45","author":"SE Cote","year":"2024","unstructured":"Cote SE, Wagshul M, Foley FW, et al. Frontal-striatal tract integrity and depression in older adults with and without multiple sclerosis. Neurol Sci. 2024;45:3359\u201368.","journal-title":"Neurol Sci"},{"key":"728_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/jon.12832","volume":"31","author":"M Palotai","year":"2021","unstructured":"Palotai M, Small C, Makris N, et al. Microstructural changes in the left mesocorticolimbic pathway are associated with the comorbid development of fatigue and depression in multiple sclerosis. J Neuroimaging. 2021;31:501\u20137.","journal-title":"J Neuroimaging"},{"key":"728_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s43856-023-00319-4","volume":"3","author":"F Riemer","year":"2023","unstructured":"Riemer F, Skorve E, Pasternak O, et al. Microstructural changes precede depression in patients with relapsing-remitting multiple sclerosis. Commun Med (Lond). 2023;3:90.","journal-title":"Commun Med (Lond)"},{"key":"728_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12311-019-01096-4","volume":"19","author":"A Lazzarotto","year":"2020","unstructured":"Lazzarotto A, Margoni M, Franciotta S, et al. Selective cerebellar atrophy associates with depression and fatigue in the early phases of relapse-onset multiple sclerosis. Cerebellum. 2020;19:192\u2013200.","journal-title":"Cerebellum"},{"key":"728_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1352458518767051","volume":"25","author":"Q van Geest","year":"2019","unstructured":"van Geest Q, Boeschoten RE, Keijzer MJ, et al. Fronto-limbic disconnection in patients with multiple sclerosis and depression. Mult Scler. 2019;25:715\u201326.","journal-title":"Mult Scler"},{"key":"728_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jnnp-2022-330109","volume":"94","author":"A Carotenuto","year":"2023","unstructured":"Carotenuto A, Valsasina P, Preziosa P, Mistri D, Filippi M, Rocca MA. Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression. J Neurol Neurosurg Psychiatry. 2023;94:94\u2013101.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"728_CR31","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1007\/s00415-023-12138-7","volume":"271","author":"D Mistri","year":"2024","unstructured":"Mistri D, Valsasina P, Storelli L, Filippi M, Rocca MA. Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation. J Neurol. 2024;271:1618\u201329.","journal-title":"J Neurol"},{"key":"728_CR32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/cells10040735","volume":"10","author":"L Speranza","year":"2021","unstructured":"Speranza L, di Porzio U, Viggiano D, de Donato A, Volpicelli F. Dopamine: the neuromodulator of long-term synaptic plasticity, reward and movement control. Cells. 2021;10:735.","journal-title":"Cells"},{"key":"728_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102537","volume":"46","author":"SW Brugger","year":"2020","unstructured":"Brugger SW, Gardner MC, Beales JT, Briggs F, Davis MF. Depression in multiple sclerosis patients associated with risk variant near NEGR1. Mult Scler Relat Disord. 2020;46: 102537.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102982","volume":"52","author":"AM Ferreira","year":"2021","unstructured":"Ferreira AM, Leal B, Ferreira I, et al. Depression and anxiety in multiple sclerosis patients: the role of genetic variability of interleukin 1beta. Mult Scler Relat Disord. 2021;52: 102982.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR35","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1212\/WNL.0000000000207457","volume":"101","author":"K Kowalec","year":"2023","unstructured":"Kowalec K, Fitzgerald KC, Salter A, et al. Polygenicity of comorbid depression in multiple sclerosis. Neurology. 2023;101:e522\u201332.","journal-title":"Neurology"},{"key":"728_CR36","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1177\/1352458521993075","volume":"27","author":"A Harroud","year":"2021","unstructured":"Harroud A, Marrie RA, Fitzgerald KC, et al. Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis. Mult Scler. 2021;27:2077\u201384.","journal-title":"Mult Scler"},{"key":"728_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbi.2021.11.022","volume":"100","author":"J Brasanac","year":"2022","unstructured":"Brasanac J, Ramien C, Gamradt S, et al. Immune signature of multiple sclerosis-associated depression. Brain Behav Immun. 2022;100:174\u201382.","journal-title":"Brain Behav Immun"},{"key":"728_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/10998004211050082","volume":"24","author":"P Newland","year":"2022","unstructured":"Newland P, Basan Y, Chen L, Wu G. Depression and inflammatory markers in veterans with multiple sclerosis. Biol Res Nurs. 2022;24:123\u20137.","journal-title":"Biol Res Nurs"},{"key":"728_CR39","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s13760-018-1015-8","volume":"120","author":"V Katarina","year":"2020","unstructured":"Katarina V, Gordana T, Svetlana MD, Milica B. Oxidative stress and neuroinflammation should be both considered in the occurrence of fatigue and depression in multiple sclerosis. Acta Neurol Belg. 2020;120:853\u201361.","journal-title":"Acta Neurol Belg"},{"key":"728_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100484","volume":"24","author":"DS Peres","year":"2022","unstructured":"Peres DS, Rodrigues P, Viero FT, et al. Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: a systematic review and meta-analysis. Brain Behav Immun Health. 2022;24: 100484.","journal-title":"Brain Behav Immun Health"},{"key":"728_CR41","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1212\/WNL.0000000000004411","volume":"89","author":"S Rossi","year":"2017","unstructured":"Rossi S, Studer V, Motta C, et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology. 2017;89:1338\u201347.","journal-title":"Neurology"},{"key":"728_CR42","first-page":"599","volume":"61","author":"M Mihalj","year":"2022","unstructured":"Mihalj M, Jankovi\u0107 Z, Jadrijevi\u0107 Kod\u017eoman E, et al. Depression and fatigue are due to obstructive sleep apnea in multiple sclerosis. Acta Clin Croat. 2022;61:599\u2013604.","journal-title":"Acta Clin Croat"},{"key":"728_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104476","volume":"70","author":"Y Akkoc","year":"2023","unstructured":"Akkoc Y, Bardak AN, Yildiz N, et al. The relationship between severity of overactive bladder symptoms and cognitive dysfunction, anxiety and depression in female patients with multiple sclerosis: running head: OAB-V8, BICAMS and HAD scale in MS. Mult Scler Relat Disord. 2023;70: 104476.","journal-title":"Mult Scler Relat Disord"},{"issue":"Suppl 4","key":"728_CR44","first-page":"511","volume":"32","author":"KI Tudor","year":"2020","unstructured":"Tudor KI, Bo\u0161njak Pa\u0161i\u0107 M, Na\u0111 \u0160kegro S, et al. Lower urinary tract symptoms and depression in patients with multiple sclerosis. Psychiatr Danub. 2020;32(Suppl 4):511\u20139.","journal-title":"Psychiatr Danub"},{"key":"728_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1590\/0004-282x-anp-2020-0400","volume":"80","author":"S Sevim","year":"2022","unstructured":"Sevim S, Demirkiran M, Terzi M, et al. Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression. Arq Neuropsiquiatr. 2022;80:168\u201372.","journal-title":"Arq Neuropsiquiatr"},{"key":"728_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102732","volume":"48","author":"K El-Salem","year":"2021","unstructured":"El-Salem K, Khalil H, Al-Sharman A, et al. Serum vitamin D inversely correlates with depression scores in people with multiple sclerosis. Mult Scler Relat Disord. 2021;48: 102732.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7224\/1537-2073.2016-040","volume":"18","author":"JM Balto","year":"2016","unstructured":"Balto JM, Ensari I, Hubbard EA, Khan N, Barnes JL, Motl RW. Individual and co-occurring SNAP risk factors: smoking, nutrition, alcohol consumption, and physical activity in people with multiple sclerosis. Int J MS Care. 2016;18:298\u2013304.","journal-title":"Int J MS Care"},{"key":"728_CR48","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/ane.13132","volume":"140","author":"CR Gascoyne","year":"2019","unstructured":"Gascoyne CR, Simpson S Jr, Chen J, van der Mei I, Marck CH. Modifiable factors associated with depression and anxiety in multiple sclerosis. Acta Neurol Scand. 2019;140:204\u201311.","journal-title":"Acta Neurol Scand"},{"key":"728_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104415","volume":"69","author":"A Saul","year":"2023","unstructured":"Saul A, Taylor BV, Blizzard L, et al. Long-term dietary acid load is associated with depression in multiple sclerosis, but less evidence was found with fatigue and anxiety. Mult Scler Relat Disord. 2023;69: 104415.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104501","volume":"70","author":"V Vong","year":"2023","unstructured":"Vong V, Simpson-Yap S, Phaiju S, et al. The association between tobacco smoking and depression and anxiety in people with multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2023;70: 104501.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1123\/japa.2021-0447","volume":"31","author":"RE Bollaert","year":"2023","unstructured":"Bollaert RE, Jones CD, Silic P, Motl RW. Depression, anxiety, and physical activity in older adults with multiple sclerosis. J Aging Phys Act. 2023;31:128\u201334.","journal-title":"J Aging Phys Act"},{"key":"728_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2596","volume":"12","author":"A Ghahremani","year":"2022","unstructured":"Ghahremani A, Mosa Farkhani S, Baniasadi M, et al. Personality traits of patients with multiple sclerosis and their correlation with anxiety and depression levels: a cross-sectional case-control study. Brain Behav. 2022;12: e2596.","journal-title":"Brain Behav"},{"key":"728_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.paid.2014.12.044","volume":"81","author":"LG Kiken","year":"2015","unstructured":"Kiken LG, Garland EL, Bluth K, Palsson OS, Gaylord SA. From a state to a trait: trajectories of state mindfulness in meditation during intervention predict changes in trait mindfulness. Pers Individ Dif. 2015;81:41\u20136.","journal-title":"Pers Individ Dif"},{"key":"728_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103651","volume":"59","author":"EJ Duraney","year":"2022","unstructured":"Duraney EJ, Schirda B, Nicholas JA, Prakash RS. Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis. Mult Scler Relat Disord. 2022;59: 103651.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR55","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s11136-020-02567-6","volume":"29","author":"JR Miller","year":"2020","unstructured":"Miller JR, Altaras C, Vissicchio NA, et al. The influence of trait mindfulness on depression in multiple sclerosis: potential implications for treatment. Qual Life Res. 2020;29:3243\u201350.","journal-title":"Qual Life Res"},{"key":"728_CR56","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12883-021-02120-z","volume":"21","author":"T Sauder","year":"2021","unstructured":"Sauder T, Keune PM, Muller R, Schenk T, Oschmann P, Hansen S. Trait mindfulness is primarily associated with depression and not with fatigue in multiple sclerosis (MS): implications for mindfulness-based interventions. BMC Neurol. 2021;21:115.","journal-title":"BMC Neurol"},{"key":"728_CR57","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/arclin\/acac025","volume":"37","author":"ML Bradson","year":"2022","unstructured":"Bradson ML, Cadden MH, Guty ET, et al. Coping style moderates the effect of pain on depression symptoms in multiple sclerosis. Arch Clin Neuropsychol. 2022;37:1515\u201326.","journal-title":"Arch Clin Neuropsychol"},{"key":"728_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103451","volume":"58","author":"DA Pimentel Maldonado","year":"2022","unstructured":"Pimentel Maldonado DA, Eusebio JR, Amezcua L, et al. The impact of socioeconomic status on mental health and health-seeking behavior across race and ethnicity in a large multiple sclerosis cohort. Mult Scler Relat Disord. 2022;58: 103451.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR59","doi-asserted-by":"crossref","unstructured":"Klenoksky B, Dargah-zada N, Shabas D. Depression in low income population with multiple sclerosis (P1.418). Neurology. 2018;90:P1.418.","DOI":"10.1212\/WNL.90.15_supplement.P1.418"},{"key":"728_CR60","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00420-015-1107-1","volume":"89","author":"TJ Kim","year":"2016","unstructured":"Kim TJ, von dem Knesebeck O. Perceived job insecurity, unemployment and depressive symptoms: a systematic review and meta-analysis of prospective observational studies. Int Arch Occup Environ Health. 2016;89:561\u201373.","journal-title":"Int Arch Occup Environ Health"},{"key":"728_CR61","first-page":"205521732312026","volume":"9","author":"KS Guerrero","year":"2023","unstructured":"Guerrero KS, Horton MK, Choudhary V, et al. Adverse childhood experiences in early life increase the odds of depression among adults with multiple sclerosis. Mult Scler J Exp Transl Clin. 2023;9:20552173231202640.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"728_CR62","volume":"16","author":"AL Miller","year":"2024","unstructured":"Miller AL, Miller LE, Bhattacharyya M, Bhattacharyya R. Depression and anxiety among sexual minorities in the United States: a cross-sectional analysis of the National Health Interview Survey. Cureus. 2024;16: e64580.","journal-title":"Cureus"},{"key":"728_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104866","volume":"77","author":"L Amezcua","year":"2023","unstructured":"Amezcua L, Livingston T, Hayward B, Zhou J, Williams MJ. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: a claims analysis of real-world data. Mult Scler Relat Disord. 2023;77: 104866.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105629","volume":"87","author":"E Asadollahzadeh","year":"2024","unstructured":"Asadollahzadeh E, Ebadi Z, Owji M, Rezaeimanesh N, Sahraian MA, Moghadasi AN. Exploring the relationship between disability status, depression, and quality of life in individuals with multiple sclerosis. Mult Scler Relat Disord. 2024;87: 105629.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102261","volume":"44","author":"M Hanna","year":"2020","unstructured":"Hanna M, Strober LB. Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020;44: 102261.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102808","volume":"50","author":"JN Cohen","year":"2021","unstructured":"Cohen JN, Seng E, Foley FW. Cognitive and motor slowing mediate the relationship between depression and falls in multiple sclerosis patients. Mult Scler Relat Disord. 2021;50: 102808.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR67","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s00415-022-11143-6","volume":"269","author":"D Sparasci","year":"2022","unstructured":"Sparasci D, Gobbi C, Castelnovo A, et al. Fatigue, sleepiness and depression in multiple sclerosis: defining the overlaps for a better phenotyping. J Neurol. 2022;269:4961\u201371.","journal-title":"J Neurol"},{"key":"728_CR68","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/ene.13029","volume":"23","author":"P Brenner","year":"2016","unstructured":"Brenner P, Burkill S, Jokinen J, Hillert J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide\u2014a cohort study. Eur J Neurol. 2016;23:1329\u201336.","journal-title":"Eur J Neurol"},{"key":"728_CR69","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1080\/19371918.2020.1810839","volume":"35","author":"E Kouchaki","year":"2020","unstructured":"Kouchaki E, Namdari M, Khajeali N, Etesam F, Asgarian FS. Prevalence of suicidal ideation in multiple sclerosis patients: meta-analysis of international studies. Soc Work Public Health. 2020;35:655\u201363.","journal-title":"Soc Work Public Health"},{"key":"728_CR70","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrneurol.2014.139","volume":"10","author":"A Feinstein","year":"2014","unstructured":"Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10:507\u201317.","journal-title":"Nat Rev Neurol"},{"key":"728_CR71","unstructured":"American Academy of Neurology: Assessment and management of psychiatric disorders in individuals with multiple sclerosis, practice guideline. 2014 . https:\/\/www.aan.com\/Guidelines\/home\/GuidelineDetail\/628. Accessed 24 Feb 2025."},{"key":"728_CR72","doi-asserted-by":"crossref","unstructured":"Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328\u201337.","DOI":"10.1191\/1352458505ms1162oa"},{"key":"728_CR73","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361\u201370.","journal-title":"Acta Psychiatr Scand"},{"key":"728_CR74","doi-asserted-by":"publisher","unstructured":"Beck AT, Steer RA, Brown G. Beck depression inventory\u2013II (BDI-II). 1996. APA PsycTests. https:\/\/doi.org\/10.1037\/t00742-000","DOI":"10.1037\/t00742-000"},{"key":"728_CR75","unstructured":"NINDS Common Data Elements: Beck Depression Inventory II (BDI-II). 2024. https:\/\/www.commondataelements.ninds.nih.gov\/report-viewer\/25193\/Beck%20Depression%20Inventory%20II%20(BDI-II). Accessed 24 Feb 2025."},{"key":"728_CR76","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/13803395.2015.1063591","volume":"37","author":"LB Strober","year":"2015","unstructured":"Strober LB, Arnett PA. Depression in multiple sclerosis: the utility of common self-report instruments and development of a disease-specific measure. J Clin Exp Neuropsychol. 2015;37:722\u201332.","journal-title":"J Clin Exp Neuropsychol"},{"key":"728_CR77","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606\u201313.","journal-title":"J Gen Intern Med"},{"key":"728_CR78","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.12688\/f1000research.25129.1","volume":"9","author":"II Kneebone","year":"2020","unstructured":"Kneebone II, Fife-Schaw C, Lam LT, das Nair R. The factor structure of the Center for Epidemiological Study\u2014depression scale in people with multiple sclerosis. F1000Res. 2020;9:1038.","journal-title":"F1000Res"},{"key":"728_CR79","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/23279095.2015.1125905","volume":"24","author":"R Green","year":"2017","unstructured":"Green R, Kalina J, Ford R, Pandey K, Kister I. SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains. Appl Neuropsychol Adult. 2017;24:183\u20139.","journal-title":"Appl Neuropsychol Adult"},{"key":"728_CR80","first-page":"205521731988598","volume":"5","author":"LD Medina","year":"2019","unstructured":"Medina LD, Torres S, Alvarez E, Valdez B, Nair KV. Patient-reported outcomes in multiple sclerosis: validation of the quality of Life in Neurological Disorders (Neuro-QoL\u2122) short forms. Mult Scler J Exp Transl Clin. 2019;5:2055217319885986.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"728_CR81","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1212\/WNL.0000000000000013","volume":"82","author":"SL Minden","year":"2014","unstructured":"Minden SL, Feinstein A, Kalb RC, et al. Guideline Development Subcommittee of the American Academy of Neurology. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:174\u201381.","journal-title":"Neurology"},{"key":"728_CR82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40120-021-00240-9","volume":"10","author":"BE Davis","year":"2021","unstructured":"Davis BE, Lakin L, Binns CC, Currie KM, Rensel MR. Patient and provider insights into the impact of multiple sclerosis on mental health: a narrative review. Neurol Ther. 2021;10:99\u2013119.","journal-title":"Neurol Ther"},{"key":"728_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s40359-022-00949-8","volume":"10","author":"E Beswick","year":"2022","unstructured":"Beswick E, Quigley S, Macdonald P, et al. The Patient Health Questionnaire (PHQ-9) as a tool to screen for depression in people with multiple sclerosis: a cross-sectional validation study. BMC Psychol. 2022;10:281.","journal-title":"BMC Psychol"},{"key":"728_CR84","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.msard.2017.12.007","volume":"20","author":"RA Marrie","year":"2018","unstructured":"Marrie RA, Zhang L, Lix LM, et al. The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. Mult Scler Relat Disord. 2018;20:9\u201315.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR85","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385\u2013401.","journal-title":"Appl Psychol Meas"},{"key":"728_CR86","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40120-020-00176-6","volume":"9","author":"J Meca-Lallana","year":"2020","unstructured":"Meca-Lallana J, Maurino J, Hernandez-Perez MA, et al. Psychometric properties of the SymptoMScreen Questionnaire in a mild disability population of patients with relapsing-remitting multiple sclerosis: quantifying the patient\u2019s perspective. Neurol Ther. 2020;9:173\u20139.","journal-title":"Neurol Ther"},{"key":"728_CR87","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.msard.2019.01.031","volume":"29","author":"KC Fitzgerald","year":"2019","unstructured":"Fitzgerald KC, Salter A, Tyry T, et al. Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. Mult Scler Relat Disord. 2019;29:86\u201393.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR88","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","volume":"78","author":"D Cella","year":"2012","unstructured":"Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology. 2012;78:1860\u20137.","journal-title":"Neurology"},{"key":"728_CR89","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1017\/neu.2019.1","volume":"31","author":"AGB Thompson","year":"2019","unstructured":"Thompson AGB, Sheldon R, Poole N, et al. A new way of rapidly screening for depression in multiple sclerosis using emotional thermometers. Acta Neuropsychiatr. 2019;31:151\u20138.","journal-title":"Acta Neuropsychiatr"},{"key":"728_CR90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12883-023-03090-0","volume":"23","author":"NY Chu","year":"2023","unstructured":"Chu NY, Watson KE, Al Hamarneh YN, Yushko L, Tsuyuki RT, Smyth P. Evaluating the impact of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a study protocol for a randomized controlled trial. BMC Neurol. 2023;23:53.","journal-title":"BMC Neurol"},{"key":"728_CR91","doi-asserted-by":"publisher","first-page":"266","DOI":"10.7224\/1537-2073.2021-103","volume":"24","author":"P Keszler","year":"2022","unstructured":"Keszler P, Maloni H, Miles Z, Jin S, Wallin M. Telemedicine and multiple sclerosis: a survey of health care providers before and during the COVID-19 pandemic. Int J MS Care. 2022;24:266\u201370.","journal-title":"Int J MS Care"},{"key":"728_CR92","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/2374373520922747","volume":"7","author":"AB Sullivan","year":"2020","unstructured":"Sullivan AB, Kane A, Roth AJ, Davis BE, Drerup ML, Heinberg LJ. The COVID-19 crisis: a mental health perspective and response using telemedicine. J Patient Exp. 2020;7:295\u2013301.","journal-title":"J Patient Exp"},{"key":"728_CR93","doi-asserted-by":"publisher","first-page":"237437352098147","DOI":"10.1177\/2374373520981474","volume":"8","author":"JR Abbatemarco","year":"2021","unstructured":"Abbatemarco JR, Hartman J, McGinley M, et al. Providing person-centered care via telemedicine in the era of COVID-19 in multiple sclerosis. J Patient Exp. 2021;8:2374373520981474.","journal-title":"J Patient Exp"},{"key":"728_CR94","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/13524585211031128","volume":"28","author":"E Longinetti","year":"2022","unstructured":"Longinetti E, Frisell T, Englund S, Reutfors J, Fang F, Piehl F. Risk of depression in multiple sclerosis across disease-modifying therapies. Mult Scler. 2022;28:632\u201341.","journal-title":"Mult Scler"},{"key":"728_CR95","doi-asserted-by":"publisher","first-page":"117957352210981","DOI":"10.1177\/11795735221098143","volume":"14","author":"LM Tardo","year":"2022","unstructured":"Tardo LM, McCreary M, Majeed H, Greenberg BM. Determining prevalence of depression and covariates of depression in a cohort of multiple sclerosis patients. J Cent Nerv Syst Dis. 2022;14:11795735221098144.","journal-title":"J Cent Nerv Syst Dis"},{"key":"728_CR96","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.msard.2018.09.008","volume":"26","author":"M Gasim","year":"2018","unstructured":"Gasim M, Bernstein CN, Graff LA, CIHR team, et al. \u201cDefining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease\u201d. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2018;26:124\u201356.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR97","doi-asserted-by":"publisher","first-page":"103837","DOI":"10.1016\/j.msard.2022.103837","volume":"63","author":"SA Glasmacher","year":"2022","unstructured":"Glasmacher SA, Kearns PK, Hassan Z, FutureMS Consortium, et al. The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2022;63:103837.","journal-title":"Mult Scler Relat Disord."},{"key":"728_CR98","unstructured":"Pimentel Maldonado D, Hemond C, Eusebio J, et al. Comorbid anxiety, depression, and fatigue symptoms by disease modifying therapy: a national multiple sclerosis cohort. Mult Scler J. 2020;26:332."},{"key":"728_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104993","volume":"79","author":"L Broch","year":"2023","unstructured":"Broch L, Flemmen HO, Simonsen CS, et al. No association between disease modifying treatment and fatigue in multiple sclerosis. Mult Scler Relat Disord. 2023;79: 104993.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR100","unstructured":"Biogen. TYSABRI (natalizumab) injection, for intravenous use prescribing information. 2023."},{"key":"728_CR101","unstructured":"Biogen. AVONEX (interferon beta-1a) injection prescribing information. 2023."},{"key":"728_CR102","unstructured":"Sanofi U.S. AUBAGIO (teriflunomide) tablets, for oral use prescribing information. 2024."},{"key":"728_CR103","unstructured":"Genzyme. LEMTRADA (alemtuzumab) injection, for intravenous use prescribing information. 2024."},{"key":"728_CR104","unstructured":"Genentech. OCREVUS (ocrelizumab) injection, for intravenous use prescribing information. 2024."},{"key":"728_CR105","unstructured":"Novartis. KESIMPTA (ofatumumab) injection, for subcutaneous use prescribing information. 2024."},{"key":"728_CR106","unstructured":"TG Therapeutics. BRIUMVI (ublituximab-xiiy) injection, for intravenous use prescribing information. 2022."},{"key":"728_CR107","unstructured":"Novartis. GILENYA (fingolimod) capsules, for oral use prescribing information. 2024."},{"key":"728_CR108","unstructured":"Novartis. MAYZENT (siponimod) tablets, for oral use prescribing information. 2024."},{"key":"728_CR109","unstructured":"Bristol Myers Squibb. ZEPOSIA (ozanimod) capsules, for oral use prescribing information. 2024."},{"key":"728_CR110","unstructured":"Janssen. PONVORY (ponesimod) tablets, for oral use prescribing information. 2024."},{"key":"728_CR111","unstructured":"EMD Serono. MAVENCLAD (cladribine) tablets, for oral use prescribing information. 2024."},{"key":"728_CR112","unstructured":"Biogen. VUMERITY (diroximel fumarate) delayed-release capsules, for oral use prescribing information. 2024."},{"key":"728_CR113","unstructured":"Biogen. TECFIDERA (dimethyl fumarate) delayed-release capsules, for oral use prescribing information. 2024."},{"key":"728_CR114","unstructured":"Teva Neuroscience. COPAXONE (glatiramer acetate) solution for subcutaneous injection prescribing information. 2023."},{"key":"728_CR115","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jpsychores.2012.08.004","volume":"73","author":"P Moore","year":"2012","unstructured":"Moore P, Hirst C, Harding KE, Clarkson H, Pickersgill TP, Robertson NP. Multiple sclerosis relapses and depression. J Psychosom Res. 2012;73:272\u20136.","journal-title":"J Psychosom Res"},{"key":"728_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103362","volume":"57","author":"CH Marck","year":"2022","unstructured":"Marck CH, Hunter A, Butler E, et al. Assessment and treatment of depression in people with multiple sclerosis: a qualitative analysis of specialist clinicians\u2019 experiences. Mult Scler Relat Disord. 2022;57: 103362.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104117","volume":"68","author":"C Tornatore","year":"2022","unstructured":"Tornatore C, Ahmad A, Pham T, et al. Identification of cognitive impairment, depression, and fatigue among multiple sclerosis patients in a large comprehensive care center: a mixed-methods, qualitative study. Mult Scler Relat Disord. 2022;68: 104117.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR118","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/pn-2023-003857","volume":"24","author":"B Stanton","year":"2024","unstructured":"Stanton B, Chalder T, Carvalho C. Cognitive behavioural therapy for neurologists. Pract Neurol. 2024;24:22\u20137.","journal-title":"Pract Neurol"},{"key":"728_CR119","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/S2589-7500(23)00109-7","volume":"5","author":"SM Gold","year":"2023","unstructured":"Gold SM, Friede T, Meyer B, et al. Internet-delivered cognitive behavioural therapy programme to reduce depressive symptoms in patients with multiple sclerosis: a multicentre, randomised, controlled, phase 3 trial. Lancet Digit Health. 2023;5:e668\u201378.","journal-title":"Lancet Digit Health"},{"key":"728_CR120","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7224\/1537-2073.2018-023","volume":"22","author":"ES Gromisch","year":"2020","unstructured":"Gromisch ES, Kerns RD, Czlapinski R, et al. Cognitive behavioral therapy for the management of multiple sclerosis-related pain: a randomized clinical trial. Int J MS Care. 2020;22:8\u201314.","journal-title":"Int J MS Care"},{"key":"728_CR121","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1177\/1352458511408753","volume":"17","author":"NB Lincoln","year":"2011","unstructured":"Lincoln NB, Yuill F, Holmes J, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17:1250\u20137.","journal-title":"Mult Scler"},{"key":"728_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105858","volume":"91","author":"A Lucien","year":"2024","unstructured":"Lucien A, Francis H, Wu W, Woldhuis T, Gandy M. The efficacy of cognitive behavioural therapy for depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. Mult Scler and Relat Disord. 2024;91: 105858.","journal-title":"Mult Scler and Relat Disord"},{"key":"728_CR123","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/archpsyc.62.9.1007","volume":"62","author":"DC Mohr","year":"2005","unstructured":"Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry. 2005;62:1007\u201314.","journal-title":"Arch Gen Psychiatry"},{"key":"728_CR124","first-page":"S31","volume":"37","author":"AP Turner","year":"2020","unstructured":"Turner AP, Knowles LM. Behavioral interventions in multiple sclerosis. Fed Pract. 2020;37:S31\u20135.","journal-title":"Fed Pract"},{"key":"728_CR125","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jpsychores.2017.12.014","volume":"106","author":"LE van den Akker","year":"2018","unstructured":"van den Akker LE, Beckerman H, Collette EH, et al. Cognitive behavioural therapy for MS-related fatigue explained: a longitudinal mediation analysis. J Psychosom Res. 2018;106:13\u201324.","journal-title":"J Psychosom Res"},{"key":"728_CR126","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13063-019-4018-8","volume":"21","author":"L Kiropoulos","year":"2020","unstructured":"Kiropoulos L, Kilpatrick T, Kalincik T, et al. Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. Trials. 2020;21:100.","journal-title":"Trials"},{"key":"728_CR127","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1177\/13524585231201089","volume":"29","author":"C Heesen","year":"2023","unstructured":"Heesen C, Berger T, Riemann-Lorenz K, et al. Mobile health interventions in multiple sclerosis: a systematic review. Mult Scler. 2023;29:1709\u201320.","journal-title":"Mult Scler"},{"key":"728_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077432","volume":"14","author":"K Henderson","year":"2024","unstructured":"Henderson K, Reihm J, Koshal K, et al. Pragmatic phase II clinical trial to improve depression care in a real-world diverse MS cohort from an academic MS centre in Northern California: MS CATCH study protocol. BMJ Open. 2024;14: e077432.","journal-title":"BMJ Open"},{"key":"728_CR129","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1080\/09638288.2022.2069292","volume":"45","author":"N Zarotti","year":"2023","unstructured":"Zarotti N, Eccles F, Broyd A, Longinotti C, Mobley A, Simpson J. Third wave cognitive behavioural therapies for people with multiple sclerosis: a scoping review. Disabil Rehabil. 2023;45:1720\u201335.","journal-title":"Disabil Rehabil"},{"key":"728_CR130","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cpr.2016.04.009","volume":"46","author":"CD Graham","year":"2016","unstructured":"Graham CD, Gouick J, Krah\u00e9 C, Gillanders D. A systematic review of the use of acceptance and commitment therapy (ACT) in chronic disease and long-term conditions. Clin Psychol Rev. 2016;46:46\u201358.","journal-title":"Clin Psychol Rev"},{"key":"728_CR131","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/AJP.0000000000000425","volume":"33","author":"LS Hughes","year":"2017","unstructured":"Hughes LS, Clark J, Colclough JA, Dale E, McMillan D. Acceptance and commitment therapy (ACT) for chronic pain: a systematic review and meta-analyses. Clin J Pain. 2017;33:552\u201368.","journal-title":"Clin J Pain"},{"key":"728_CR132","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s11136-021-03033-7","volume":"31","author":"S Neate","year":"2022","unstructured":"Neate S, Humam A, Nag N, Jelinek GA, Simpson-Yap S. Greater mastery is associated with lower depression risk in a large international cohort of people with multiple sclerosis over 2.5 years. Qual Life Res. 2022;31:1789\u201398.","journal-title":"Qual Life Res"},{"key":"728_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2020.110252","volume":"138","author":"A Ratajska","year":"2020","unstructured":"Ratajska A, Glanz BI, Chitnis T, Weiner HL, Healy BC. Social support in multiple sclerosis: associations with quality of life, depression, and anxiety. J Psychosom Res. 2020;138: 110252.","journal-title":"J Psychosom Res"},{"key":"728_CR134","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/1352458518807082","volume":"25","author":"P Soelberg Sorensen","year":"2019","unstructured":"Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G. The multiple sclerosis care unit. Mult Scler. 2019;25:627\u201336.","journal-title":"Mult Scler"},{"key":"728_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105540","volume":"85","author":"L Van Hijfte","year":"2024","unstructured":"Van Hijfte L, Cambron M, Capron B, et al. Multiple sclerosis multidisciplinary care: a national survey and lessons for the global community. Mult Scler Relat Disord. 2024;85: 105540.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR136","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.msard.2019.01.029","volume":"29","author":"MA Kotb","year":"2019","unstructured":"Kotb MA, Kamal AM, Aldossary NM, Bedewi MA. Effect of vitamin D replacement on depression in multiple sclerosis patients. Mult Scler Relat Disord. 2019;29:111\u20137.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR137","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jns.2017.04.017","volume":"378","author":"L Rolf","year":"2017","unstructured":"Rolf L, Muris A-H, Bol Y, Damoiseaux J, Smolders J, Hupperts R. Vitamin D3 supplementation in multiple sclerosis: symptoms and biomarkers of depression. J Neurol Sci. 2017;378:30\u20135.","journal-title":"J Neurol Sci"},{"key":"728_CR138","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.msard.2017.10.004","volume":"18","author":"N Nathoo","year":"2017","unstructured":"Nathoo N, Mackie A. Treating depression in multiple sclerosis with antidepressants: a brief review of clinical trials and exploration of clinical symptoms to guide treatment decisions. Mult Scler Relat Disord. 2017;18:177\u201380.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR139","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1871527322666230321093133","volume":"23","author":"A Gil-Sanchez","year":"2024","unstructured":"Gil-Sanchez A, Canudes M, Valcheva P, et al. Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study. CNS Neurol Disord Drug Targets. 2024;23:395\u2013401.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"728_CR140","first-page":"682","volume":"12","author":"F Haddad","year":"2022","unstructured":"Haddad F, Dokmak G, Karaman R. The efficacy of cannabis on multiple sclerosis-related symptoms. Life (Basel). 2022;12:682.","journal-title":"Life (Basel)"},{"key":"728_CR141","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"C Collin","year":"2010","unstructured":"Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32:451\u20139.","journal-title":"Neurol Res"},{"key":"728_CR142","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"A Novotna","year":"2011","unstructured":"Novotna A, Mares J, Ratcliffe S, Sativex Spasticity Study Group, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122\u201331.","journal-title":"Eur J Neurol"},{"key":"728_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116739","volume":"413","author":"JC Ouallet","year":"2020","unstructured":"Ouallet JC, Radat F, Creange A, et al. Evaluation of emotional disorders before and during treatment with interferon beta in patients with multiple sclerosis. J Neurol Sci. 2020;413: 116739.","journal-title":"J Neurol Sci"},{"key":"728_CR144","doi-asserted-by":"publisher","first-page":"239821282311852","DOI":"10.1177\/23982128231185290","volume":"7","author":"CC Nunes","year":"2023","unstructured":"Nunes CC, Abreu P, Correia F, Mendes I, da Silva AM. Teriflunomide treatment outcomes in multiple sclerosis: a Portuguese real-life experience. Brain Neurosci Adv. 2023;7:23982128231185290.","journal-title":"Brain Neurosci Adv"},{"key":"728_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102659","volume":"47","author":"J de Seze","year":"2021","unstructured":"de Seze J, Devy R, Planque E, et al. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study. Mult Scler Relat Disord. 2021;47: 102659.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR146","doi-asserted-by":"publisher","first-page":"104677","DOI":"10.1016\/j.msard.2023.104677","volume":"73","author":"J Wilken","year":"2023","unstructured":"Wilken J, Traboulsee A, Nelson F, LEM-COG investigators, et al. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Mult Scler Relat Disord. 2023;73:104677.","journal-title":"Mult Scler Relat Disord."},{"key":"728_CR147","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.1007\/s00415-022-11134-7","volume":"269","author":"LG Hvid","year":"2022","unstructured":"Hvid LG, Stenager E, Dalgas U. Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study. J Neurol. 2022;269:4895\u2013908.","journal-title":"J Neurol"},{"key":"728_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103780","volume":"61","author":"JRG Bonitto","year":"2022","unstructured":"Bonitto JRG, Ayala OD, Botero LC. Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia. Mult Scler Relat Disord. 2022;61: 103780.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR149","first-page":"205521732110046","volume":"7","author":"CM Hersh","year":"2021","unstructured":"Hersh CM, Kieseier B, de Moor C, et al. Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS. Mult Scler J Exp Transl Clin. 2021;7:20552173211004630.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"728_CR150","doi-asserted-by":"publisher","first-page":"100","DOI":"10.7224\/1537-2073-14.2.100","volume":"14","author":"KR Edwards","year":"2012","unstructured":"Edwards KR, Goodman WA, Ma CY. Improvement of neuropsychological function in cognitively impaired multiple sclerosis patients treated with natalizumab: a preliminary study. Int J MS Care. 2012;14:100\u20134.","journal-title":"Int J MS Care"},{"key":"728_CR151","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2020-000108","volume":"3","author":"K Smoot","year":"2021","unstructured":"Smoot K, Chen C, Stuchiner T, Lucas L, Grote L, Cohan S. Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study. BMJ Neurol Open. 2021;3: e000108.","journal-title":"BMJ Neurol Open"},{"key":"728_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104109","volume":"68","author":"E Manchon","year":"2022","unstructured":"Manchon E, Laplaud D, Vukusic S, et al. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: final results from the PRO-MSACTIVE study. Mult Scler Relat Disord. 2022;68: 104109.","journal-title":"Mult Scler Relat Disord"},{"key":"728_CR153","first-page":"205521732110075","volume":"7","author":"BI Glanz","year":"2021","unstructured":"Glanz BI, Zurawski J, Casady EC, et al. The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:20552173211007524.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"728_CR154","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200185","volume":"13","author":"I Kister","year":"2023","unstructured":"Kister I, Oh C, Douglas EA, et al. No increase in symptoms toward the end of the ocrelizumab infusion cycle in patients with multiple sclerosis: symptom burden on ocrelizumab: a longitudinal study (SymBOLS). Neurol Clin Pract. 2023;13: e200185.","journal-title":"Neurol Clin Pract"},{"key":"728_CR155","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2215-0366(14)00049-2","volume":"2","author":"A Fischer","year":"2015","unstructured":"Fischer A, Schroder J, Vettorazzi E, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. Lancet Psychiatr. 2015;2:217\u201323.","journal-title":"Lancet Psychiatr"},{"key":"728_CR156","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1745-6215-12-259","volume":"12","author":"CL Cooper","year":"2011","unstructured":"Cooper CL, Hind D, Parry GD, et al. Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial. Trials. 2011;12:259.","journal-title":"Trials"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00728-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:03:47Z","timestamp":1747652627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["728"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00728-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amy B. Sullivan received consulting and speaker fees from Biogen, Bristol Myers Squibb, EMD, Genentech, and Novartis. Bryan Davis has nothing to disclose. Julie Kidd has served on advisory boards for EMD, Serono, and Novartis. Horacio Chiong-Rivero is a paid speaker for Biogen and Janssen, has served on advisory board for Genentech, and has received fellowship grant support from the National MS Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}